Summary
Johnson & Johnson (JNJ) announced the completion of its acquisition of Ci:z Holdings Co., Ltd. on January 16, 2019. The acquisition, initially announced on October 23, 2018, was valued at approximately $2.1 billion, with a total purchase price of ¥230 billion. This strategic move integrates Ci:z Holdings, known for its Dr Ci:Labo, Labo Labo, and Genomer skincare brands, into Johnson & Johnson's Consumer Companies segment. The acquisition was primarily executed through an all-cash tender offer, acquiring 89% of Ci:z Holdings' outstanding shares. Johnson & Johnson plans to acquire the remaining shares in the first half of 2019 through a share consolidation, leading to the delisting of Ci:z Holdings from the Tokyo Stock Exchange. Investors can expect any earnings per share (EPS) impact from this transaction to be detailed within Johnson & Johnson's 2019 guidance, which will be provided during their Q4 2018 earnings call.
Key Highlights
- 1Johnson & Johnson has successfully completed the acquisition of Ci:z Holdings Co., Ltd. as of January 16, 2019.
- 2The total purchase price for the acquisition was approximately $2.1 billion (¥230 billion).
- 3Ci:z Holdings, a Japanese skincare company, will be integrated into Johnson & Johnson's Family of Consumer Companies.
- 4The acquisition was completed through an all-cash tender offer, securing 89% of Ci:z Holdings' outstanding shares.
- 5Johnson & Johnson intends to acquire the remaining shares and delist Ci:z Holdings from the Tokyo Stock Exchange in the first half of 2019.
- 6The financial impact on EPS will be disclosed in JNJ's 2019 guidance during the Q4 2018 earnings call.